Autopsy report · NCT03839940

Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

“Severe lack of accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 3 years 2 months before it stopped.
• 39 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Alliance for Clinical Trials in Oncology

Sponsor type

University, hospital or other

Conditions

Malignant Neoplasm

Interventions

Dexamethasone; Placebo; Questionnaire; Quality-of-Life Assessment; Everolimus

Participants

39

Sites

319

Countries

United States

Trials that died the same way

• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (90% match in meaning)
• T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation
  “Lack of accrual” (90% match in meaning)
• Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
  “Lack of adequate accrual.” (88% match in meaning)
• Estrogen Patch for COVID-19 Symptoms
  “Poor accrual” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.